Core Insights - Labcorp reported $3.33 billion in revenue for Q4 2024, a year-over-year increase of 9.8% and a surprise of +0.44% over the Zacks Consensus Estimate of $3.32 billion [1] - The EPS for the same period was $3.45, compared to $3.30 a year ago, with an EPS surprise of +1.47% against the consensus estimate of $3.40 [1] Revenue Performance - Biopharma Laboratory Services generated $767 million, exceeding the estimated $747.52 million, representing a +10.4% change year-over-year [4] - Diagnostics Laboratories reported revenues of $2.59 billion, slightly above the estimated $2.57 billion, reflecting a +10.2% change compared to the previous year [4] Operating Income - Adjusted Operating Income for Biopharma Laboratory Services was $130.80 million, surpassing the average estimate of $123.15 million [4] - Adjusted Operating Income for Diagnostics Laboratories was $359.50 million, which fell short of the average estimate of $382.85 million [4] Stock Performance - Labcorp's shares have returned +6.7% over the past month, outperforming the Zacks S&P 500 composite's +2.1% change [3] - The stock currently holds a Zacks Rank 2 (Buy), indicating potential for outperformance in the near term [3]

Core Viewpoint - Labcorp Holdings reported better-than-expected earnings and revenues for the fourth quarter of 2024, showcasing strong organic and inorganic growth, although margins contracted [11][12]. Financial Performance - Adjusted EPS for Q4 2024 was $3.45, a 4.5% increase year-over-year, beating the Zacks Consensus Estimate by 1.5% [1][2]. - GAAP EPS for Q4 was $1.70, compared to a loss of $1.95 in the same period last year [2]. - Total revenues for Q4 rose 9.8% year-over-year to $3.33 billion, surpassing the Zacks Consensus Estimate by 0.6% [3][4]. - For the full year, adjusted EPS was $14.57, up 7.4% from the previous year, and also exceeded the Zacks Consensus Estimate by 0.4% [2][4]. Revenue Breakdown - Diagnostics Laboratories segment reported revenues of $2.59 billion, reflecting a 10.2% year-over-year improvement [5]. - Biopharma Laboratory Services revenues increased by 10.4% to $767 million, driven by organic growth of 8.9% [6]. - Organic revenues for the quarter were up 5.4%, with a 6.2% rise in the Base Business, partially offset by a 0.8% decline in COVID-19 testing [3][6]. Margin Analysis - Gross margin contracted by 16 basis points to 26.9% due to a 9.1% rise in the cost of revenues [7]. - Adjusted operating income improved by 4.4% year-over-year to $301.1 million, but the adjusted operating margin contracted by 47 basis points to 9% [7]. Cash Position - Labcorp ended Q4 with cash and cash equivalents of $1.52 billion, significantly up from $536.8 million at the end of 2023 [8]. - Long-term debt totaled $5.33 billion, a 31.5% increase from the previous quarter [8]. - Cumulative cash inflow from operating activities was $1.59 billion, compared to $1.20 billion at the end of 2023 [8]. Future Guidance - Total revenues for 2025 are expected to grow between 6.7% and 8%, with Diagnostics Laboratories revenues projected to increase by 6.5% to 7.7% [9]. - Full-year adjusted EPS for 2025 is expected to be in the range of $14.57 to $15.60, with the Zacks Consensus Estimate at $15.97 [9]. Strategic Developments - Labcorp is enhancing its Global Trial Connect to speed up clinical trials and expanding its Labcorp OnDemand test menu [11][12]. - The company introduced a companion diagnostic assay for gastric cancer patients, marking a significant advancement in targeted treatment [12].

Core Viewpoint - Labcorp reported quarterly earnings of $3.45 per share, exceeding the Zacks Consensus Estimate of $3.40 per share, and showing an increase from $3.30 per share a year ago, indicating a positive earnings surprise of 1.47% [1] Financial Performance - Labcorp's revenues for the quarter ended December 2024 were $3.33 billion, surpassing the Zacks Consensus Estimate by 0.44%, and up from $3.03 billion year-over-year [2] - The company has consistently outperformed consensus EPS and revenue estimates over the last four quarters [2] Stock Performance - Labcorp shares have increased approximately 9% since the beginning of the year, compared to a 3.1% gain in the S&P 500 [3] - The stock currently holds a Zacks Rank 2 (Buy), indicating expectations of outperforming the market in the near future [6] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $3.90 on revenues of $3.42 billion, and for the current fiscal year, it is $15.97 on revenues of $13.84 billion [7] - The trend of estimate revisions for Labcorp has been favorable leading up to the earnings release [6] Industry Context - The Medical - Dental Supplies industry, to which Labcorp belongs, is currently ranked in the bottom 40% of over 250 Zacks industries, which may impact stock performance [8]

FOR IMMEDIATE RELEASE Media Investors Media@Labcorp.com Investor@labcorp.com Labcorp Announces 2024 Fourth Quarter and Full Year Results Company Provides 2025 Guidance BURLINGTON, N.C., February 6, 2025 – Labcorp Holdings Inc. (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced results for the fourth quarter ended December 31, 2024, and provided 2025 guidance. "In 2024, Labcorp delivered exceptional results driven by both organic and inorganic growth," said Adam ...

Company Provides 2025 Guidance Results from Continuing Operations versus last year: Revenue: Q4 of $3.33 billion vs $3.03 billion; Full year of $13.01 billion vs $12.16 billion Diluted EPS: Q4 of $1.70 vs $(1.95); Full year of $8.84 vs $4.33 Adjusted EPS: Q4 of $3.45 vs $3.30; Full year of $14.57 vs $13.56 Free Cash Flow: Q4 of $665.1 million vs $412.4 million; Full year of $1.10 billion vs $748.7 million Announced 10 transactions and launched new innovative tests meeting significant unmet medical needs ...

The upcoming report from Labcorp (LH) is expected to reveal quarterly earnings of $3.40 per share, indicating an increase of 3% compared to the year-ago period. Analysts forecast revenues of $3.31 billion, representing an increase of 9.3% year over year.The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.Ahead of a company's earnings disclosure, it is cruc ...

Labcorp Holdings Inc. (LH) , or Labcorp, is slated to report its fourth-quarter 2024 results on Feb. 6 before the opening bell.Find the latest EPS estimates and surprises on Zacks Earnings Calendar.The renowned laboratory service provider reported adjusted earnings of $3.50 in the last reported quarter, topping the Zacks Consensus Estimate by 0.56%. Labcorp surpassed estimates in each of the trailing four quarters, the average surprise being 2.87%.LH’s Q4 EstimatesThe Zacks Consensus Estimate for Labcorp’s ...

Labcorp (LH) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended December 2024. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on February 6. On ...

BURLINGTON, N.C., Jan. 10, 2025 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today that the company will participate in a fireside chat at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, Jan. 14, at 3:45 p.m. (PT). A live audio webcast of the fireside chat will be available via the Company Investor Relations website at ir.Labcorp.com and archived for replay.  About LabcorpLabcorp (NYSE: LH) is a global leader of innovative a ...

If you are looking for a stock that has a solid history of beating earnings estimates and is in a good position to maintain the trend in its next quarterly report, you should consider Labcorp (LH) . This company, which is in the Zacks Medical - Dental Supplies industry, shows potential for another earnings beat.This medical laboratory operator has seen a nice streak of beating earnings estimates, especially when looking at the previous two reports. The average surprise for the last two quarters was 2.40%.Fo ...